Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Revenio Group Oyj is a Finnish health technology company and a global leader in ophthalmological devices and software solutions. It develops and commercializes effective, easy-to-use screening devices for detecting significant public health diseases, particularly in eye care. Its flagship offerings under the iCare brand include intraocular pressure (IOP) measurement devices known as tonometers, perimeter and fundus imaging devices, and the Oculo eye care software platform, which supports clinical communication, telehealth, remote patient monitoring, and data analytics. These tools aid physicians in diagnosing conditions such as glaucoma, diabetic retinopathy, and macular degeneration (AMD), enhancing efficiency and quality in ophthalmic diagnostics. Headquartered in Vantaa, Finland, Revenio Group Oyj operates through subsidiaries across regions including Finland, the USA, Italy, Australia, the UK, China, and the Netherlands, serving healthcare professionals worldwide in the medical devices sector.
€12.20
+€0.09 (+0.74%)
EOD Jul 2, 2026
Margins and capital returns are both well above average: 23.17% operating margin, ROIC at 15.75%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 6.0%, steady but not accelerating.
Even for strong businesses, today's 21x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
20.7x earnings, 18.8x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€111M
▲ +6.0% YoY
Net Income (TTM)
€16M
▼ -5.9% YoY
Op. Margin
19.04%
▼ -1.0pp YoY
ROIC
15.75%
Cash Flow & Balance Sheet
FCF (TTM)
€18M
▲ +32.2% YoY
Op. Cash Flow (TTM)
€19M
▲ +30.2% YoY
Net Debt
-€15M
Net Cash Position
Cash & Equiv.
€26M
3Y CAGR: +4.2%
3Y CAGR: +7.0%
Continue Research
At a P/E of 20.7 and a price-to-free-cash-flow of 18.8, Revenio Group Oyj (REG1V.XHEL) trades above a two-stage DCF intrinsic value of about €11.82 per share, so at €12.20 the stock looks overvalued (3.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Revenio Group Oyj scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 3.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €11.82 per share for REG1V.XHEL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €8.87. At today's €12.20, that puts the stock about 3.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Revenio Group Oyj scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 19.0% operating margin and a 15.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Revenio Group Oyj pays a regular dividend of about €0.39 per share per year (typically in quarterly installments), a yield of roughly 3.2% at the current price. That is a payout ratio of about 67.7% of earnings, so the dividend is covered, with less cushion. Revenio Group Oyj has grown the dividend at roughly 5.8% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For REG1V.XHEL's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. REG1V.XHEL currently trades above its estimated intrinsic value and scores 50/100 on quality (mixed). It also yields about 3.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.